Aimei Health Technology Co., Ltd. (Nasdaq: AFJK) is a pre-deal Cayman Islands special purpose acquisition company (SPAC) that delivered its 6/30/2026 second-quarter print on August 13, and the only material event of the period was the July 7, 2026 termination of the United Hydrogen Group Inc. merger agreement that had been the issuer's defined target for more than two years. The Q2 10-Q, the 8/6/2026 extension filing, and the spot price of $12.20 against a $12.005 per-share trust value (computed by dividing the $12,488,393 trust account by the 1,040,332 public shares remaining) tell the same story: the equity is being priced almost exactly at the trust floor, and the discount to the $10.00 par redemption value has compressed from a 52-week low of $6.75 to roughly 18 cents of premium over trust, which we read as the market's assessment that the SPAC is in orderly wind-down mode rather than in active search for a substitute target.
The thesis is straightforward: with twenty-one of the twenty-four permitted monthly extensions already consumed and the 36-month combination period expiring on December 6, 2026, Aimei Health has, in our view, at most three additional one-month extensions and roughly four calendar months to either close an entirely new business combination or commence winding up. The trust account of $12.49 million earns interest in 185-day U.S. Treasuries, the deferred underwriting fee of $690,000 is contractually waived by the underwriters if no deal closes (and the $690,000 then flows to the redeeming public shareholders), and the net liability stack of $4.53 million ($3.84 million current liabilities plus the $690,000 deferred underwriter fee) is fully covered by sponsor loans. We see no catalyst that would push the equity meaningfully above the trust floor in the absence of a new deal announcement, and the dominant risk is that no alternative target emerges, in which case the SPAC redeems public shares at par plus accrued interest and dissolves.
The load-bearing risk is the absence of a publicly identified replacement target. The 8/6/2026 21st extension current report still references "the date on which the Company consummates a business combination with United Hydrogen," a stale reference in a post-termination filing that suggests management has not pivoted the loan documents to a substitute target, and the company's stated healthcare-innovation focus (small-cap biopharmaceutical, medical technology, medical device, and diagnostics companies in North America, Europe, and Asia Pacific) constrains the pool of plausible deals to a market segment where the comparable 2024-2026 SPAC pipeline has produced zero completed transactions in this size tier. The falsifiable clock is the September 6, 2026 termination date set by the 21st extension, the next 10-Q expected in mid-November 2026, and any 8-K disclosing either a new letter of intent or an EGM notice for a substitute deal.